Evert B. Schimmelpennink's Net Worth
-$59.2 Thousand
Who is Evert B. Schimmelpennink?
Evert B. Schimmelpennink does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Pfenex Inc., iBio, Inc., LENZ Therapeutics, Inc., and Contineum Therapeutics, Inc..
SEC CIK
Evert B. Schimmelpennink's CIK is 0001713795
Past Insider Trading and Trends
2024 was Evert B. Schimmelpennink's most active year for acquiring shares with 6 total transactions. Evert B. Schimmelpennink's most active month to acquire stocks was the month of January. 2020 was Evert B. Schimmelpennink's most active year for disposing of shares, totalling 6 transactions. Evert B. Schimmelpennink's most active month to dispose stocks was the month of September. 2018 saw Evert B. Schimmelpennink paying a total of $50,385.00 for 232,956 shares, this is the most they've acquired in one year. In 2018 Evert B. Schimmelpennink cashed out on 11,236 shares for a total of $37,977.68, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Pfenex Inc. No price found
See RemarksEvert B. Schimmelpennink used to own units in Common Stock but no longer holds any shares there. From 2017 to 2020 Evert B. Schimmelpennink acquired a total of 37,894 shares in Pfenex Inc. at a cost of $50,385.00, Evert also disposed a total of 27,894 shares of Pfenex Inc. equalling to $37,977.68.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -26.66K |
—
|
—
|
0
|
Oct 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
| +60.03% | 10K |
$5.04 | $50,385.00 | 26.66K |
Sep 11
| |||
Form 4
|
∞
| 16.66K |
$3.38 | -$37,977.68 | 16.66K |
Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
iBio, Inc. (IBIO) Snapshot price: $1.75
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
LENZ Therapeutics, Inc. (GRPH) No price found
President, CEO and SecretaryEvert B. Schimmelpennink owns 45,000 units of Common Stock. In the year 2024 Evert B. Schimmelpennink filed a total of 3 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 45K |
$1.04 | $46,800.00 | 45K |
Jul 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Contineum Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||